Oral vancomycin shows efficacy against CDI in both low and high doses

A study by researchers at Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University found that oral vancomycin, for the treatment of Clostridium difficile infections, showed efficacy at low and high doses.

The data was presented Tuesday at the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy conference in Denver. Patients with CDI were treated with oral vancomycin at the low dose of 125mg every six hours and the high dose of more than 125mg every six hours; 85 and 86 percent of patients, respectively, saw clinical improvements within 72 hours.

CDI is an infection occurring in the large bowel. It can result in stomach pain, severe cramping, severe diarrhea and death. CDI is a contributing factor in 14,000 deaths annually in the U.S., according to the Centers for Disease Control and Prevention.

"This study's comparable results in low dose and high dose antibiotic treatment of CDI reinforce the importance of considering new approaches to using these medications," Clinical Pharmacy Manager in Infectious Diseases, Montefiore Medical Center and assistant professor of medicine, Department of Medicine (Infectious Diseases), Einstein, Phillip Chung said. "Antibiotic stewardship is an important focus in hospitals today. We are using our study findings to develop treatment guidelines that encourage low dose treatment."

The study included data from approximately 300 patients hospitalized at Montefiore between 2005 and 2010 that were diagnosed with CDI-associated diarrhea.